1-20 of 91
Jennifer A. Woyach
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia

Clinical Trials & Observations
John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O'Brien, M.D., Jennifer R. Brown, Deborah M. Stephens, Jacqueline Barrientos, Stephen Devereux, Peter Hillmen, John M. Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, William George Wierda
Journal: Blood
Blood blood.2020009617.
DOI: https://doi.org/10.1182/blood.2020009617
Published: 2021
Includes: Supplemental data
Journal Articles

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib

Adrian Wiestner, MD PhD, Paolo Ghia, MD PhD, John C. Byrd, MD, Inhye E Ahn, MD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Daniel Jones, MD PhD, Leo W. K. Cheung, PhD, Elizabeth Chong, PhD, Kevin Kwei, PhD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Jennifer A. Woyach, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
DOI: https://doi.org/10.1182/blood-2020-134386
Published: 2020
Journal Articles

Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy

Leylah Azali, PharmD, Lindsay Hazelden, PharmD, Tracy Wiczer, PharmD, Marilly Palettas, Rebekah Thomas, Connor Aossey, James S. Blachly, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Kerry A. Rogers, MD, John C. Byrd, MD, Jennifer A. Woyach, MD, Daniel Addison, MD, Seema A Bhat, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 29–30.
DOI: https://doi.org/10.1182/blood-2020-137800
Published: 2020
Journal Articles

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

Anthony R. Mato, MD, John M. Pagel, MDPhD, Catherine C. Coombs, MD, Nirav N. Shah, MD, Nicole Lamanna, MD, Ewa Lech-Marańda, MD PhD, Toby A. Eyre, Jennifer A. Woyach, MD, William G. Wierda, MD PhD, Chan Yoon Cheah, MBBS, Lindsey E Roeker, MD, Manish R. Patel, MD, Bita Fakhri, MDMPH, Minal Barve, MD, Constantine S. Tam, MBBS, David John Lewis, MD, James N. Gerson, MD, Alvaro J. Alencar, MD, Justin Taylor, MD, Omar Abdel-Wahab, MD, Paolo Ghia, MD PhD, Stephen J. Schuster, MD, Jessica Chen, MS, Binoj Nair, PhD, Donald Tsai, MD PhD, Nora C. Ku, MD, Matthew S. Davids, MD, Jennifer R Brown, MD PhD, Wojciech Jurczak, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–37.
DOI: https://doi.org/10.1182/blood-2020-134970
Published: 2020
Journal Articles

Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Daniel Goldstein, MD, Kyle A. Beckwith, MDPhD, Cecelia Miller, PhD, Ying Huang, MS, MA, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, David A. Bond, MD, John C. Byrd, MD, Michael R. Grever, MD, Nyla A Heerema, PhD, Kerry A. Rogers, MD, Amy S. Ruppert, PhD, Jennifer A. Woyach, MD, Adam S. Kittai, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
DOI: https://doi.org/10.1182/blood-2020-136714
Published: 2020
Journal Articles

Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, Corinne Hoffman, MS, CNP, Kami J. Maddocks, MD, Gerard Lozanski, MD, Adam S. Kittai, MD, Mollie E. Moran, Mark Reid, CNP, Jennifer A. Woyach, MD, John C. Byrd, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
DOI: https://doi.org/10.1182/blood-2020-137655
Published: 2020
Journal Articles

Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

Jennifer A. Woyach, MD, James S. Blachly, MD, Kerry A. Rogers, MD, Seema A Bhat, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Mojgan Jianfar, MD, Gerard Lozanski, MD, David M. Weiss, Barbara L. Andersen, PhD, Priti Patel, MD, Veerendra Munugalavadla, PhD, Anna Butturini, MD, Yan Xu, Min Hui Wang, PhD, John C. Byrd, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–18.
DOI: https://doi.org/10.1182/blood-2020-136317
Published: 2020
Journal Articles

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Matthew C. Cheung, MDMSc, Nicole Mittmann, PhD, Carolyn Owen, MDFRCPC, Nizar Abdel-Samad, MD, Graeme Fraser, Selay Lam, MDBSc,FRCPC, Michael Crump, MD, Catherine Sperlich, Richard van der Jagt, Stephen Couban, MDBSc, Jennifer A. Woyach, MD, Amy S. Ruppert, PhD, Allison M Booth, Sumithra J Mandrekar, PhD, Gail T. McDonald, Lois E. Shepherd, Anca Prica, MD, Hope Yen, Bingshu E. Chen, Annette E. Hay
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–30.
DOI: https://doi.org/10.1182/blood-2020-136692
Published: 2020
Journal Articles

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study

Michael Wang, MD, Nirav N. Shah, MD, Alvaro J. Alencar, MD, James N. Gerson, MD, Manish R. Patel, MD, Bita Fakhri, MDMPH, Wojciech Jurczak, MD PhD, Xuan Ni Tan, MD, Katharine L Lewis, MBBS, Timothy S. Fenske, MD, Catherine C. Coombs, MD, Ian W. Flinn, MD PhD, David John Lewis, MD, Steven Le Gouill, MD PhD, M. Lia Palomba, MD, Jennifer A. Woyach, MD, John M. Pagel, MDPhD, Nicole Lamanna, MD, Jonathon B. Cohen, MDMS, Minal Barve, MD, Paolo Ghia, MD PhD, Toby A. Eyre, Ming Yin, Binoj Nair, PhD, Donald Tsai, MD PhD, Nora C. Ku, MD, Anthony Mato, MD, Chan Yoon Cheah, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–10.
DOI: https://doi.org/10.1182/blood-2020-134314
Published: 2020
Journal Articles

Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

Seema A Bhat, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, James S. Blachly, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Kerry A. Rogers, MD, Gerard Lozanski, MD, Nyla A Heerema, PhD, Lynne V. Abruzzo, MD PhD, Cecelia Miller, PhD, Jennifer Zvosec, CCRP, Kasturi Ganesh-Barki, MBBS, John C. Byrd, MD, Jennifer A. Woyach, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
DOI: https://doi.org/10.1182/blood-2020-138612
Published: 2020
Journal Articles

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BT K/PLCG2 mutations

Fabienne Lucas, Karylin Larkin, C. Thomas Gregory, Shelley Orwick, Tzyy-Jye Doong, Arletta Lozanski, Gerard Lozanski, Shrilekha Misra, Apollinaire Ngankeu, Hatice Gulcin Ozer, Deepa Sampath, Shanmugapriya Thangavadivel, Selen A. Yilmaz, Kerry A. Rogers, John C. Byrd, Jennifer A. Woyach, James S. Blachly
Journal: Blood
Blood (2020) 135 (24): 2192–2195.
DOI: https://doi.org/10.1182/blood.2019003722
Published: 2020
Includes: Supplemental data
Journal Articles

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Clinical Trials & Observations
John C. Byrd, William G. Wierda, Anna Schuh, Stephen Devereux, Jorge M. Chaves, Jennifer R. Brown, Peter Hillmen, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline Barrientos, John M. Pagel, Jennifer A. Woyach, Kathleen Burke, Todd Covey, Michael Gulrajani, Ahmed Hamdy, Raquel Izumi, Melanie M. Frigault, Priti Patel, Wayne Rothbaum, Min Hui Wang, Susan O’Brien, Richard R. Furman
Journal: Blood
Blood (2020) 135 (15): 1204–1213.
DOI: https://doi.org/10.1182/blood.2018884940
Published: 2020
Includes: Supplemental data
Journal Articles

Hypertension and incident cardiovascular events following ibrutinib initiation

Clinical Trials & Observations
Tyler Dickerson, Tracy Wiczer, Allyson Waller, Jennifer Philippon, Kyle Porter, Devin Haddad, Avirup Guha, Kerry A. Rogers, Seema Bhat, John C. Byrd, Jennifer A. Woyach, Farrukh Awan, Daniel Addison
Journal: Blood
Blood (2019) 134 (22): 1919–1928.
DOI: https://doi.org/10.1182/blood.2019000840
Published: 2019
Includes: Supplemental data
Journal Articles

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Clinical Trials & Observations
Jennifer A. Woyach
Journal: Blood
Blood (2019) 134 (21): 1796–1801.
DOI: https://doi.org/10.1182/blood.2019001321
Published: 2019
Journal Articles

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia

Brian Giacopelli, Qiuhong Zhao, Amy S. Ruppert, Akwasi Agyeman, Christoph Weigel, Yue-Zhong Wu, Madelyn M. Gerber, Kari G. Rabe, Melissa C. Larson, Junyan Lu, James S. Blachly, Kerry A. Rogers, William G. Wierda, Jennifer R. Brown, Kanti R. Rai, Michael Keating, Laura Z. Rassenti, Thomas J. Kipps, Thorsten Zenz, Tait D. Shanafelt, Neil E. Kay, Lynne V. Abruzzo, Kevin R. Coombes, Jennifer A. Woyach, John C. Byrd, Christopher C. Oakes
Journal: Blood
Blood (2019) 134 (8): 688–698.
DOI: https://doi.org/10.1182/blood.2019000490
Published: 2019
Includes: Supplemental data
Journal Articles

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Clinical Trials & Observations
John C. Byrd, Peter Hillmen, Susan O’Brien, Jacqueline C. Barrientos, Nishitha M. Reddy, Steven Coutre, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Patrick Thornton, Carol Moreno, Marco Montillo, John M. Pagel, Jan A. Burger, Jennifer A. Woyach, Sandra Dai, Remus Vezan, Danelle F. James, Jennifer R. Brown
Journal: Blood
Blood (2019) 133 (19): 2031–2042.
DOI: https://doi.org/10.1182/blood-2018-08-870238
Published: 2019
Includes: Supplemental data
Journal Articles

Exploring LAG-3 Expression in Multiple Myeloma Patients Following Autologous Stem Cell Transplant

Lucas Fabienne, PhD, Michael Pennell, PhD, Don M. Benson, Jr., MD PhD, Yvonne Efebera, MD, Maria Chaudhry, MD, Jennifer A. Woyach, MD, Xiangnan Guan, Zhang Suohui, Christin E Burd, PhD, Ashley E. Rosko, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3434.
DOI: https://doi.org/10.1182/blood-2018-99-119577
Published: 2018
Journal Articles

Incidence, Type, and Management of Venous and Arterial Thrombosis during Ibrutinib Treatment

Elizabeth Kander, MD, Qiuhong Zhao, MS, Tracy Wiczer, John C. Byrd, MD, Jennifer A. Woyach, MD, Farrukh T. Awan, MD MS, Kerry A. Rogers, MD, Tzu-Fei Wang, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3148.
DOI: https://doi.org/10.1182/blood-2018-99-110556
Published: 2018
Journal Articles

A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies

Jennifer A. Woyach, MD, Ian W. Flinn, MD PhD, Deborah M. Stephens, Farrukh T. Awan, MD MS, Kerry A. Rogers, MD, Sean D. Reiff, Ron E. Savage, Sudharshan Eathiraj, Lyndsey A. Szuszkiewicz, Kate Tith, John C. Byrd, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3136.
DOI: https://doi.org/10.1182/blood-2018-99-116338
Published: 2018
Journal Articles

Hypertension Development, Management, and Cardiovascular Events Following Ibrutinib Initiation for Hematologic Malignancies

Tyler Dickerson, PharmD, Tracy Wiczer, Allyson Waller, Jennifer Philippon, Devin Haddad, Avirup Guha, Kyle Porter, Kerry A. Rogers, MD, Jennifer A. Woyach, MD, John C. Byrd, MD, Daniel Addison, Farrukh T. Awan, MD MS
Journal: Blood
Blood (2018) 132 (Supplement 1): 4423.
DOI: https://doi.org/10.1182/blood-2018-99-110345
Published: 2018